Cypress Bioscience, Inc. to Present at UBS Global Life Sciences Conference
SAN DIEGO, CA–(Marketwire – September 22, 2010) – Cypress Bioscience, Inc. ( NASDAQ : CYPB ) today announced that Jay D. Kranzler, MD, PhD, its Chairman of the Board and Chief Executive Officer, will present at the UBS Global Life Sciences Conference today, September 22, 2010.
Read more:
Cypress Bioscience, Inc. to Present at UBS Global Life Sciences Conference
Cypress Bioscience, Inc. to Present at Baird’s 2010 Health Care Conference
SAN DIEGO, CA–(Marketwire – September 15, 2010) – Cypress Bioscience, Inc. ( NASDAQ : CYPB ) today announced that Jay D.
Read more:
Cypress Bioscience, Inc. to Present at Baird’s 2010 Health Care Conference
Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism
SAN DIEGO, CA–(Marketwire – 08/26/10) – Cypress Bioscience, Inc. (NASDAQ: CYPB – News ), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, today announced that it has acquired patent rights and technology related to a novel, intranasal formulation of carbetocin, a potential breakthrough treatment for the core symptoms of …
See the original post here:
Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism
Cypress Bioscience Licenses Alexza Pharmaceutical’s Staccato(R) Nicotine
SAN DIEGO, CA–(Marketwire – 08/26/10) – Cypress Bioscience, Inc. (NASDAQ: CYPB – News ) today announced that it has licensed Alexza Pharmaceutical’s (NASDAQ: ALXA – News ) Staccato nicotine technology — a novel electronic multidose delivery technology designed to help people stop smoking. The innovative Staccato nicotine technology is intended to improve on a well-validated smoking cessation …
Excerpt from:
Cypress Bioscience Licenses Alexza Pharmaceutical’s Staccato(R) Nicotine
Cypress Bioscience Sends Letter to Ramius
SAN DIEGO, CA–(Marketwire – August 17, 2010) – Cypress Bioscience, Inc. ( NASDAQ : CYPB ) today announced that its Board of Directors has sent a letter to Ramius LLC in response to Ramius’ letter dated August 11, 2010.
See the rest here:
Cypress Bioscience Sends Letter to Ramius
Cypress Bioscience Announces Second Quarter 2010 Financial Results
SAN DIEGO, CA–(Marketwire – August 9, 2010) – Cypress Bioscience, Inc. ( NASDAQ : CYPB ) today announced financial results for the second quarter of 2010. The Company reported total revenue of $9.1 million for the quarter ended June 30, 2010, which includes commercial revenues of $8.1 million and revenues under collaborative agreement of $0.8 million
Read more here:
Cypress Bioscience Announces Second Quarter 2010 Financial Results
Cypress Bioscience In-Licenses BioLineRx’s Novel Antipsychotic
SAN DIEGO, CA–(Marketwire – 06/20/10) – Cypress Bioscience, Inc. (NASDAQ: CYPB – News ) announced that Cypress has entered into an exclusive North American license for the development and commercialization of BioLineRx’s novel antipsychotic (BL-1020, hereafter, CYP-1020), a potential breakthrough treatment for schizophrenia. Specific terms of the transaction were not disclosed, but the total …
Read more here:
Cypress Bioscience In-Licenses BioLineRx’s Novel Antipsychotic
Cypress Bioscience Announces First Quarter 2010 Financial Results
SAN DIEGO, CA–(Marketwire – May 10, 2010) – Cypress Bioscience, Inc. ( NASDAQ : CYPB ) today announced financial results for the first quarter of 2010
More here:
Cypress Bioscience Announces First Quarter 2010 Financial Results
Cypress Bioscience Announces 2009 Financial Results (Marketwire)
SAN DIEGO, CA–(Marketwire – March 31, 2010) – Cypress Bioscience, Inc. ( NASDAQ : CYPB ) today announced financial results for the quarter and year ended December 31, 2009.
Read the rest here:
Cypress Bioscience Announces 2009 Financial Results (Marketwire)
Cypress Bioscience Announces Third Quarter 2009 Financial Results (Marketwire)
SAN DIEGO, CA–(Marketwire – November 9, 2009) – Cypress Bioscience, Inc.
Here is the original post:
Cypress Bioscience Announces Third Quarter 2009 Financial Results (Marketwire)
